CLINICAL TRIAL

The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression.

The primary objective of this study is to evaluate the efficacy of 25 mg of psilocybin under supportive conditions to adult participants with BP-II, current episode depressed, in improving depressive symptoms.

Open source BibTeX RIS

Bibliographic context

Journal: ClinicalTrials.gov
Date: 2022-10-24
Source: ClinicalTrials.gov
DOI: Unavailable
PubMed: Unavailable

Authors

Sheppard Pratt Health System

Watch author

Topics and keywords

psilocybin Depression Safety Other Treatment Resistant Depression Psilocybin UNKNOWN

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Blocking 5-HT2B receptors abolishes psilocybin’s efficacy in the rat forced swim testJournal of Psychopharmacology · 2026-06-22 Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17 Psilocybin and Mental Health Outcomes: Scoping Review with ☸SAIMSARASAIMSARA Journal · 2026-06-14 Efficacy of Psilocybin-Assisted Therapy in Major Depressive Disorder: A Systematic Review and Meta-AnalysisPsychiatry International · 2026-06-14 Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-05-31 Psilocybin-induced neurocardiogenic syncope: a case reportPsychopharmacology · 2026-05-27 Psilocybin for Treatment-Resistant Depression: A Comprehensive Review of Mechanisms and Therapeutic PotentialDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21 The Use of Psilocybin for Managing Refractory Behavioral Health Conditions: A New and Promising ApproachDigital Showcase Research, Scholarship, & Creative Works (University of Lynchburg) · 2026-05-21